

**Workshop**

**Joint SEAR-WPR workshop  
to plan the accelerated  
implementation of  
new WHO TB policies**



**1-4  
APRIL  
2025**

**Hanoi,  
Viet Nam**

**Topical issues and  
forthcoming updates to TB  
screening recommendations  
and implementation guidance**




Cecily Miller

WHO Global Programme on  
Tuberculosis & Lung Health,  
Geneva, Switzerland

# Global progress towards the Ending TB

We are **far off** our targets for the End TB Strategy and the 2023 UN High-Level Meeting

- Progress in reducing global incidence is stalled in much of the world
- Case detection is higher than ever but still short of our targets
- TPT coverage is improving but still very far from targets
- Almost one half of all people with TB face catastrophic costs




90% target for 2027

People living with HIV newly enrolled on ART


Household contacts of people newly diagnosed with TB

# One challenge – Asymptomatic TB



**Figure 3: Proportion of tuberculosis disease that is subclinical by two definitions, and by country**  
The left panel is aggregated over the full 12-country dataset. The right panel is disaggregated by country.

# Another challenge – barriers to reaching care



Shete et al IJTLD 2015

# Systematic screening for TB

**Systematic TB Screening can improve global TB care by:**

- **Protecting individuals at high risk**
  - Reduces delays in diagnosis
  - Improves treatment outcomes
  - Reduces costs for patients, families
- **Improving TB epidemiology of the community**
  - Increases detection of TB
  - Reduces transmission of TB
  - Reduces TB prevalence and incidence
- **Preventing TB entirely**
  - Enables initiation of TB preventive therapy







# Overview of guidelines

- Released **March 2021**, composed of 17 recommendations
- Two main types of recommendations
  - **Who to screen** – risk groups, settings
  - **How to screen** – recommended tools
- Same intervention, two distinct objectives

Screening done for **individual protection** – to ensure people at high risk of TB get early detection and care, or preventive therapy, to avoid advanced disease and death

Screening done for **community benefit** – to reduce prevalence, transmission, incidence of TB



<https://tbksp.who.int/en/node/1274>

# Recommendations: populations to be screened

**TB screening is strongly recommended for:**



**Household and  
close contacts**



**People living  
with HIV**



**Miners exposed  
to silica dust**



**Prisoners**

**These populations should always be screened in all global settings.**

# Recommendations: populations to be screened

TB screening is strongly recommended for:



**Child contacts of  
people with TB**



**Children living with  
HIV**

- **Very high risk of TB**
- **Higher risk of rapid progression from infection to disease**



# Recommendations: populations to be screened

## TB screening is conditionally recommended for:

### Facility-based screening/ intensified case finding (ICF):

People with risk factors for TB seeking health-care service in settings with  $\geq 0.1\%$  TB prevalence

- ✓ Malnourishment
- ✓ Diabetes
- ✓ History of previous TB
- ✓ Chronic lung disease
- ✓ Health care workers
- ✓ Those with other risk factors for TB

People with untreated fibrotic lesions on chest X-ray

### Community-based screening/ active case finding (ACF):


People with structural risk factors for TB and limited access to health care

- ✓ Urban poor
- ✓ Homeless
- ✓ Refugees
- ✓ Migrants
- ✓ Other vulnerable, marginalized groups

People in settings with 0.5% TB prevalence

**Prioritization is needed depending on the setting, context.**

# Recommendations: tools for screening (>15 years)



- **Chest X-ray**
- **Computer-aided detection (CAD)**

- Highly sensitive for TB disease
- Can detect TB before onset of symptoms
- CAD approved in place of human reading of CXR for adults (>15 y)



## **Symptom screening:**

- **Cough**
- **Multiple symptom**

- Feasible and easy to implement
- Low resource requirements
- Not highly accurate
- Does not detect everyone with TB



## **Rapid molecular tests**

- Less sensitive as screening tool but highly specific
- Still requires a follow-up test

# Recommendations: tools for screening people with HIV

For adults & adolescents (>10 years) living with HIV:



## Chest X-ray & CAD

- Improves the sensitivity of screening, particularly among those in regular ART care
- CAD only recommended for those 15 years & older



## C-Reactive Protein

- A general marker of inflammation, can be used as a point-of-care test
- Increases specificity of screening, particularly among those not yet on ART



## WHO 4-symptom screen (W4SS)

- Any one of cough, fever, night sweats, weight loss
- Recommended to be done at every health visit



## Rapid molecular tests

- Can be used for screening all people living with HIV
- Strongly recommended for acutely ill and hospitalized patients in a “test and treat” strategy directly to guide treatment

# Recommendations: tools for screening children



## For child contacts of TB patients ( $\leq 15$ years)



- Symptom screening (cough, fever, weight loss/lack of weight gain, reduced playfulness)
- Chest X-ray

## For children living with HIV ( $\leq 10$ years)



- Symptom screening (cough, fever, weight loss/lack of weight gain, reduced playfulness)
- Contact with TB patient

# Screening guidelines– updates coming soon

- January 2025 – Technical Advisory Group meeting on CAD
  - Evaluation of CAD products as a stopgap measure while WHO PQ in development
  - Evaluated 8 currently available CAD products for diagnostic accuracy
  - Results available April 2025
- Updated Target Product Profiles for new TB screening tools
  - Expert consultation and public commentary held 2024
  - Update available 2025
- Future guideline updates for TB screening
  - Pediatric CAD software, other screening tools
  - Expanding the WHO evaluation of CAD beyond TB
  - Updates to screening tools and interventions to address asymptomatic TB

# Operational handbook




The handbook provides

- Support on developing context-specific screening approaches
- A sound basis for national guidelines based on TB epidemiology in different risk groups and the health care system in the country

Target audience:

- Staff in national TB programmes and national HIV/AIDS programmes
- Other health programmes involved in screening in public and private sectors
- Communities and implementing partners




<https://tbksp.who.int/en/node/1275>



# Operational handbook

## What are the principles of implementing high-quality, ethical screening practices?



# Operational handbook

## How to create, implement, and update a national TB screening strategy?

Assessing the situation


Setting goals and  
specific objectives

Monitoring, evaluation,  
and modifying the  
programme

Identifying and  
prioritizing risk groups

Planning, budgeting  
and implementing

Choosing algorithms for  
prioritized risk groups



# Operational handbook

What are different screening models, and what are the pros and cons of them?



**Health facilities**



**Residential, occupational, penitentiary settings**



**Community events and gatherings**



**Mobile outreach screening campaign**



**Home**

## **Institution-based screening approaches**


- Can increase efficiency
- Will not reach remote or isolated populations

## **Community-based screening approaches**

- Can increase reach and coverage
- Higher resource requirements


# Operational handbook - algorithms

## Single screening test algorithm



Utilizes one screening test to distinguish between people who possibly have TB and are referred for TB diagnostic evaluation, and people who most likely don't have TB and can be assessed for TPT


## Parallel screening algorithm



Utilizes two screening tests together – a positive or abnormal on either or both test is an indication for diagnostic evaluation


# Operational handbook - algorithms

## Positive sequential screening algorithm



Uses two screening tests - only those positive on the first test going on to a second screen, and only those positive on both screens go on for diagnosis



## Negative sequential screening algorithm



Uses two screening tests - those positive on the first test go straight to diagnostic evaluation, those negative on the first test go on to a second screen – thus those positive on both or either screens go on for diagnosis

# Operational handbook

## How to monitor and evaluate TB screening?



<b>Implementation indicators</b>	
Acceptability or Reach/coverage	B / A
Screening positivity rate	C / B
Screening retention in care	D / C
Testing positivity rate	E / D
Yield	E / A
Linkage to care	F / E
Treatment success	G / F
NNS	B / E

### **Population-level impact indicators**

Incidence (~reduction in notified cases despite activities)  
Prevalence (if being measured by intervention)  
TB Mortality





# Useful tools - *ScreenTB*

## **ScreenTB**

- **Web-based tool to assist countries with prioritization of risk groups for screening and selection of screening tools and algorithms**
- **Harnesses data from a variety of sources – WHO Global TB Report, UN HIV data, published literature**
- **Produces estimates of yield and cost of screening, allowing for comparison between risk groups and across algorithm options within groups**
- **Creates figures to allow for easy visual analysis**

[ScreenTB.org](https://ScreenTB.org)



# Operational handbook – updates coming soon

- CAD – a pragmatic approach to threshold selection
  - Being developed with colleagues from MSF, based on implementation experience
  - A programmatic alternative to conducting a CAD calibration study
  - Feasible to implement rapidly, to enable CAD use when data or resources not available for full CAD calibration study
- Further implementation guidance for specific screening approaches
  - Facility-based screening
  - Community-based screening – a roadmap for scaling up TB screening
  - Risk group-specific screening (e.g. prisoners, miners, PLHIV, contacts)
  - “Best bet” algorithms for specific risk groups, settings

# Acknowledgements

Dennis Falzon, Saskia den Boon, other WHO staff at HQ, Regional, Country Offices  
Patients  
Evidence Reviewers  
National TB and HIV Programmes  
Guideline Development Group, External Review Group  
FIND, Stop TB Partnership, IoM  
TAG, civil society  
Global Fund, USAID  
Other experts and funding agencies



## © WORLD HEALTH ORGANIZATION 2025

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.